FMED ETF — Fidelity Disruptive Medicine ETF

Fidelity Disruptive Medicine ETF (FMED)

Updated October 16, 2026.

FMED is an ETF. its expense ratio is 0.50%. Total return is 20.4% over the past 3.3 years, 63.4 points behind SPY at 83.8%.

Fidelity Disruptive Medicine ETF is an equity ETF that invests at least 80% of its assets in companies developing innovative and unconventional approaches to medicine and healthcare delivery that could displace traditional industry incumbents; the fund is non-diversified and carries an expense ratio of 0.50%. The fund does not currently distribute, though it did make a special one-time distribution in the past that should not be expected to recur regularly. This ETF appeals to growth-oriented investors seeking exposure to emerging healthcare innovation rather than those prioritizing current income.

FMED performance versus SPY

Price and return data through 2026-10-16.

Total return is 20.4% over the past 3.3 years, 63.4 points behind SPY at 83.8%. Over the past year its total return — price change plus distributions reinvested — is 16.3%. Its deepest 1-year drawdown was 18.3%.

FMED key facts

Issuer

Fidelity Investments

Asset type

ETF

Asset class

Equity

Inception date

04/16/2020

Expense ratio

0.50%

Distribution frequency

None

Last close

$30.29 (as of 2026-10-16)

AUM

$51,419,076

Average volume

17541.0

Ex-dividend date

12/20/2024

Payment date

12/24/2024

Beta

0.74

How Dividend Vision calculates yield and returns

Distribution rate (the posted rate) uses calculation basis unavailable. Issuer rates can use a different denominator and date, including ex-date NAV. Trailing-12-month yield is the sum of split-adjusted cash distributions with ex-dates in the last 12 months, divided by the published price. It lags a recent raise or cut. Total return uses split-adjusted close with distributions reinvested on the ex-dividend date (a modeling convention, not the cash-settlement date) from the first stored bar on or after inception through the latest bar, compared with the same window on the benchmark. That is the security's total return, not your personal gain/loss.

Yield and safety methodology · Distribution rate methodology · Distribution Safety Score methodology

Sources and review

Primary sources: Fidelity Investments; prices and distributions from Dividend Vision, derived from vendor EOD data.

Reviewed by Bert Sweet, CEO and Co-owner of Dividend Vision. Methodology: Distribution Safety Score.

FMED risks and drawbacks

Total return has trailed SPY over the available window. The deepest 1-year drawdown on record here is 18.3%.

Who may consider FMED — and who may not

It is a weaker fit for investors who need monthly cash flow (FMED does not currently distribute); investors whose main goal is matching SPY total return. This is educational context, not a recommendation to buy or sell.

More on FMED

• All tickers starting with F

Frequently asked questions

More securities from Fidelity Investments.